Becton Dickinson (BOX) AI Stock Analysis

1 Followers

Becton Dickinson

(BX Swiss:BOX)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring consumables and workflow integrationBD's recurring consumables and embedded clinical workflows can support repeat purchasing across hospitals, laboratories, and pharmaceutical customers. Standardization and switching costs reinforce customer retention, while instrument-linked reagents and services broaden the recurring revenue base over the next several quarters.

Negative Factors

Weak recent revenue and profitabilityRecent revenue contraction and weaker net-margin conversion indicate that stable gross and EBITDA margins have not fully translated into bottom-line performance. Lower ROE also signals reduced earnings power relative to the equity base, limiting near-term returns from the business.

Becton Dickinson (BOX) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 57.91B
Dividend Yield: 2.21%
Average Volume (3M): ―
Price to Earnings (P/E): 51.2
Beta (1Y): ―
Revenue Growth: ―
EPS Growth: ―
Country: Switzerland
Employees: 60,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Becton Dickinson Business Overview & Revenue Model

Company Description

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, a...

Becton Dickinson Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q4-2026)|% Change Since:0.00%|Next Earnings Date:Feb 04, 2027

Earnings Call SentimentPositive

The call was strongly positive, supported by strong Q4 revenue and adjusted EPS growth, broad-based momentum across key platforms, share gains, improved cash flow, productivity gains, innovation progress, and a completed portfolio transformation. The main challenges were the Alaris comparison, low-single-digit fiscal 2027 revenue guidance, flat reported operating margins, inflation and tariff effects, and the Q4 vaccine decline, but management characterized several of these pressures as temporary or moderating and expressed confidence in continued growth and margin expansion beyond fiscal 2027.

Positive Updates

Strong Fourth-Quarter and Full-Year Results

Q4 revenue was $5.3 billion, up 5.6%, and adjusted EPS was $4.15, up 27.3%. Full-year revenue was $19.5 billion, up 3.9%, and adjusted EPS was $12.70, up 6.7%.

Negative Updates

Fiscal 2027 Revenue Guidance Moderates

BD expects fiscal 2027 full-year revenue growth in the low single digits. At the midpoint, growth excluding the Alaris capital comparison is expected to be mid-single digit, while currency is expected to be a headwind of about 70 basis points.

Company Guidance

For fiscal 2027, BD expects low single-digit growth for the full year, with currency estimated to be a headwind of about 70 basis points and an approximate 200 basis points impact from the Alaris capital comparison; excluding this impact, BD expects mid-single-digit growth at the midpoint of its guidance. Adjusted operating margins are expected to be roughly flat year-over-year, the adjusted tax rate is expected to be between 16% and 17%, weighted average shares outstanding are expected to be approximately 273 million, and adjusted EPS is expected to be in a range of $13.10 to $13.30. Q1 revenue growth is expected to be at the low end of the range, the first half is expected to be in line with the midpoint of the full year guidance, and Q1 adjusted EPS is expected to be between $2.32 and $2.37, with earnings growth expected to accelerate in Q2 and the second half of the year.

Becton Dickinson Risk Analysis

Becton Dickinson disclosed 25 risk factors in its most recent earnings report. Becton Dickinson reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Becton Dickinson Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:BOX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WST	78Outperform	$28.74B	45.99	21.08%	0.22%	12.60%	32.05%
MDLN	65Neutral	$53.82B	61.06	4.97%	―	11.85%	-57.19%
ICUI	64Neutral	$4.55B	75.56	2.81%	―	-5.82%	―
TFX	57Neutral	$6.16B	18.66	9.74%	0.88%	-29.30%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	45Neutral	$13.67B	-19.14	-11.62%	0.15%	5.33%	-164.67%

* Healthcare Sector Average

Performance Comparison

CH:BOX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:BOX	Becton, Dickinson and Co	236.53	0.00	0.00%
BAX	Baxter International Inc	26.42	7.76	41.56%
ICUI	ICU Medical	182.11	43.58	31.46%
TFX	Teleflex	155.30	47.07	43.48%
WST	West Pharmaceutical Services, Inc.	412.55	146.68	55.17%
MDLN	Medline, Inc. Class A	40.91	-0.09	-0.22%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Becton Dickinson AI Stock Analysis